Had a conversation with INVESTOR RELATIONS yesterday.
1) I expressed concern obviously about the share price, dilution, and how we can feasibly expect an up-list without a R/S this year, as they stated they wanted to do in the 2018 expectations.
- The general idea was that up-listing isn't going to happen overnight, and definitely will not happen if the time is not right. From the second I began the conversation, he expressed his disappointment in the share price. It seems it is still in their best interest to only up-list when things are looking different. Obviously thats a hard sight to envision right now with the daily dilution, and he wasn't able to share much more on this besides that things are progressing and that they are in the best position yet as a company. If you wanna hear his take on that, please reach out to him, thats the general theme I gathered.
2) I asked why the Tear Sheet is not up to date with accurate O/S.
- He said that the tear sheet is managed by a third party company that updates the investor portion of their website. He said he would reach out to them about this and would follow up with me. When talking about this as well, he did confirm that the only convertible notes out there are Eagle.
3) I confirmed that Mann's purchases are coming directly from his own wallet and in no way any funds come from the money raised by the company.
4) No updates on "relevant scientific meeting" that was stated in 10/13/17 PR for preclinical post MI-remodeling data. Also asked whats next for this part of the pipeline, in which he wasn't able to tell me any new info either besides what they originally stated.
5) No updates on ShareIntel, it sounds like they have received much interest about this recently and he has passed the concerns forward, but had nothing to share at the time.
6) No updates on SofPulse sales other than what's been stated, but they believe this revenue stream will be huge for their company.
Discussed a few other things with him but these were the main points. From my take on things, It sounds that they are just as frustrated about the PPS as us, believe they are unfairly valued, and still believe there are good things in store, and definitely positive updates to come. I think the biggest thing with this stock is everyone's timeframe and expectations. Ive always had a longterm mindset here, and my biggest concern that goes hand in hand with that is the fear of a R/S one day out of the blue, which it sounds is the last thing they want to do. As long as that remains the same, I personally am fine waiting longer for rewards to be gained here. Yes its frustrating and it sucks but an arbitrary opportunity is an arbitrary opportunity. The point is, we know we are undervalued here, and we know one day, the right kind of news, such as buying back of Eagle convertible notes or big SofPulse sales or partnership opportunities will make this thing run. Even if they just got tired one day and sold the company for 0.25 a share, Id still be a very happy camper. Point is, Endonovo is definitely worth more than their current share price, and I definitely believe there are better days for us to come.
And lastly, my closing thoughts, don't sit here and talk down on management without at least reaching out to them first. It's one thing to raise concerns, and another to continuously ridicule them without at least hearing their perspective on things. I just wanted to give a little insight into what was told to me, as I feel other longs concerns are consistent with mine. This is my fourth time talking to Steve since I became a shareholder here over a year ago. Any shareholder with questions of their own should reach out to him, he has always been very open to scheduling time to talk through any questions one may have.
Don't know why the heck this got deleted the first time, got reviewed and still deemed off topic so lets try this again. Cheers.
AI
